Slides
Page 1
Executing Today While Building for Tomorrow © 2025 Esperion Therapeutics, Inc. All rights reserved. J.P. Morgan Healthcare Conference I January 2026 Sheldon Koenig, President and CEO
Page 2
Forward-looking Statements & Disclosures This investor presentation contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding marketing strategy and commercialization and business development plans, current and planned operational expenses, expected profitability, future operations, commercial products, clinical development, plans for potential future product candidates, financial condition and outlook, including expected cash runway and profitability, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “suggest,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions. Any express or implied statements contained in this investor presentation that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause Esperion’s actual results to differ significantly from those projected, including, without limitation, the net sales, profitability, and growth of Esperion’s commercial products, clinical activities and results, supply chain, commercial development and launch plans, business development, the outcomes and anticipated benefits of legal proceedings and settlements, and the risks detailed in Esperion’s filings with the Securities and Exchange Commission. Any forward-looking statements contained in this investor presentation speak only as of the date hereof, and Esperion disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this investor presentation, other than to the extent required by law. © 2025 Esperion Therapeutics, Inc. All rights reserved.2
Page 3
Esperion at a Glance © 2025 Esperion Therapeutics, Inc. All rights reserved.3 Partnerships & Pipeline Triple Combination NEXT-GENERATION ORAL LIPID-LOWERING COMBINATIONS Bempedoic acid, ezetimibe, and statin (atorvastatin or rosuvastatin) ESP-2001 NEXT-GENERATION ACLY INHIBITOR Indication: Primary Sclerosing Cholangitis (PSC) Discovery Programs EXPANDING BEYOND CARDIOVASCULAR DISEASE Emerging product candidates with the potential to address multiple forms of chronic kidney disease, including both broad and rare indications Reach Sustainable Profitability in 2026 Durable Cash Flows Strong Balance Sheet Attractive P&L Profile Strong Financial PositionCommercial
Page 4
Multi-Year Proven Track Record of Execution © 2025 Esperion Therapeutics, Inc. All rights reserved.4 Consistent U.S. Commercial Execution • Delivered strong year-over-year revenue and TRX growth • Expanded the product label, significantly broadening the U.S. addressable patient population to more than 70 million patients • Achieved broad national commercial and Medicare payer coverage • Secured ANDA settlements highlighting potential longer term exclusivity runway Global Partner Execution • Japan: Successfully executed the commercial launch • Canada: Secured regulatory approval for NEXLETOL • Europe: Achieved inclusion in ESC/EAS guidelines as a Class I, Level A recommendation Disciplined Financial Management • Strengthened the capital structure • Meaningfully reduced debt • Positioned to support continued commercial expansion, pipeline advancement, and strategic BD in 2026 and beyond Pipeline Execution • Advanced the pipeline with selection of ESP-2001 selected as a lead preclinical candidate for PSC • Progressed triple combination program • Initiated early renal discovery programs
Page 5
2025 A Pivotal Year; the Strongest in Esperion’s History © 2025 Esperion Therapeutics, Inc. All rights reserved.5 +35% to 38% Y/Y growth FY 2025 PRELIMINARY U.S. NET PRODUCT SALES PRELIMINARY YE 2025 CASH & CASH EQUIVALENTS RETAIL PRESCRIPTION EQUIVALENTS Y/Y +20% to 23% Y/Y +55% to 59% excluding one-time milestones TOTAL PRELIMINARY REVENUE
Page 6
Commercial Execution Drove Significant Growth in 2025 © 2025 Esperion Therapeutics, Inc. All rights reserved.6 1 Cheeley MK, et al. J Clin Lipidol. 2022 Jul-Aug;16(4):361-375 Growing adoption +34% Retail Prescription Equivalents Y/Y Prescriber base expanded ~25% Y/Y , now ~45,000 prescribing HCPs Broad payer coverage established >90% commercial lives / >90% Medicare Clear Commercial Focus: Statin-intolerant and statin-resistant patients (~30% overall market 1) Winning Commercial Strategy: Balanced in-person & digital promotion, including piloted DTC efforts & invested in competitive reimbursement initiatives LARGE, UNDERPENETRATED MARKET ~70M addressable patients in the U.S.
Page 7
Year in Review Highlights of 2025 © 2025 Esperion Therapeutics, Inc. All rights reserved.7 U.S. Commercial Growth PRELIMINARY U.S. NET PRODUCT SALES OF $156M to $160M Market Exclusivity FOUR ANDA SETTLEMENTS, INCLUDING DR.REDDY’S Balance Sheet Progress $55M OF DEBT REPAID Pipeline Advancement TRIPLE-COMBINATION PROGRAM, PSC (ESP- 2001), RENAL DISEASE Global Expansion TWO NEW PARTNERSHIPS AND ONE LAUNCH Partner Milestones $91M IN TOTAL MILESTONES RECEIVED
Page 8
Our Vision 2040 is grounded in proven execution and defines how we scale Esperion into a global, multi-product pharmaceutical company.
Page 9
From Execution to Ambition © 2025 Esperion Therapeutics, Inc. All rights reserved.9 Achieve at least 5 marketed products by 2040 through a combination of BD and internal pipeline advancement Strengthen and Expand the Bempedoic Acid Franchise Build a Diversified, Multi-Product Portfolio Advance the Next- Generation ACLY Pipeline • Continue to unlock the multi billion-dollar potential of the NEXLETOL/NEXLIZET franchise • Leverage established U.S. commercial infrastructure to support product acquisitions, co-promotions, in-licensing, and revenue-share partnerships • Build a diversified portfolio of internally developed, wholly owned ACLY inhibitors globally targeting rare and orphan diseases
Page 10
Strengthen and Expand the Bempedoic Acid Franchise
Page 11
Major Catalysts to Drive Growth in 2026 and Beyond © 2025 Esperion Therapeutics, Inc. All rights reserved.11 U.S. Guideline Momentum Expected inclusion in U.S. guidelines in early 2026 Oral Triple Combination Lifecycle management opportunity Market Exclusivity Potential expansion supported by initial ANDA settlements International Expansion Milestone payments and royalty revenues Commercial Investment Continued sales and marketing expansion Improved Gross Margins Tech transfer with European partner
Page 12
Oral Triple Combination Opportunity © 2025 Esperion Therapeutics, Inc. All rights reserved.12 1. Product in development, not approved, LDL-C data based on literature evaluating co administered products (Rubino et.al Atherosclerosis 320 (2021) 122-128, Mahajan et.al. J. Clin. Lipidology (2004), Vol 18 (5) e867-872; 2. USPI for Zetia (November 2024), monotherapy and on statin; 3. New Amsterdam Pharma corporate presentation (Jan 2025); 4. USPIs for Repatha (Nov 2024), Praluent (March 2024), Leqvio (July 2024) and Lerochol (Dec 2025) No head-to-head studies have been conducted; cross-study data reflect different study designs, populations, and other features. In development ~ 60% - 70% Once daily Approved/Generic 19% Once daily In development 33% Once daily 4 approved products ~ 48% - 71% Bi-weekly to 6 months Triple Combo1 Ezetimibe2 Obicetrapib3 PCSK9i4 Approval Status LDL-C reduction Administration Dosing Highly compelling efficacy: published literature suggests >60% LDL-C reduction Oral option with injectable-like efficacy Builds directly on the bempedoic acid franchise, leveraging existing commercial infrastructure Approval anticipated in 2027
Page 13
Bempedoic Acid: Partner-Led Expansion Outside the U.S. © 2025 Esperion Therapeutics, Inc. All rights reserved.13 Multi-Billion $ Global Opportunity Provides Additional Revenue Streams APPROVED IN 41 Countries globally Partner Highlights Milestones and Royalties Israel JapanEurope, Asia & South America Australia & New Zealand Canada Daiichi Sankyo Europe / Daiichi Sankyo Co., Ltd. Otsuka Pharmaceutical Co., Ltd. • Included in ESC/EAS guidelines as a Class I, Level A recommendation • Introduced oral triple- combination therapy • >600,000 patients treated to date • Regulatory approval and reimbursement for NILEMDO in France • Approval anticipated in the first half of 2026 • NILEMDO approved in Q4 2025 • Expects approval for NEXLIZET in 2026 • Approval anticipated in Q4 2026 Neopharm Israel HLS TherapeuticsCSL Seqirus • Launched in December 2025 with favorable pricing • Represents the third largest cardiovascular prevention market globally Tiered royalties and additional sales milestones Tiered royalties and additional sales milestones Tiered royalties and additional milestones Upfront and near-term milestone payments Upfront payment, milestones and tiered royalties
Page 14
Build a Diversified, Multi-Product Portfolio
Page 15
Portfolio Growth Through Partnerships © 2025 Esperion Therapeutics, Inc. All rights reserved.15 Leverage established U.S. commercial infrastructure and expertise to expand product portfolio Partner of choice across synergistic call points Multiple opportunities for product acquisitions, in-licensing, co- promotions, and revenue share partnerships Cardiometabolic Heart Failure Lipid Management Obesity Rare and OrphanKidney Therapeutic Area Focus Each a multi-billion dollar market opportunity on its own Each to reach millions of patients in need Each can create considerable value
Page 16
Advance the Next-Generation ACLY Pipeline
Page 17
Leveraging a World-Class ACLY Platform to Expand the Pipeline © 2025 Esperion Therapeutics, Inc. All rights reserved.17 Deep expertise in ACLY biology, a target with broad potential across multiple disease pathways Actively advancing programs in renal disease Lead preclinical candidate ESP-2001 for the treatment of primary sclerosing cholangitis (PSC) Structure & ligand based virtual screening toolbox Virtual Screening Structure-based approach using in-house protein structures Knowledge Base Novel rapid-fire mass spectrometry High Throughput Screening Multiple Lead Compounds ~500~400,000~8,000,000 COMPOUNDSCOMPOUNDS COMPOUNDS
Page 18
PSC: High Unmet Need Driving Significant Market Opportunity © 2025 Esperion Therapeutics, Inc. All rights reserved.18 PSC: primary sclerosing cholangitis EU: 30K3-5US: 46K1-2 2024 Diagnosed Prevalence of PSC ~76K Annual Market Opportunity Estimate • No approved therapies with proven efficacy to cure or halt PSC progression • Potential Orphan Drug Designation & Fast Track Approval • Discovery program is internally developed and wholly-owned globally • IND-enabling studies initiated, with the goal of submitting an IND and beginning first-in-human studies in 2026 >$1B PSC: A Rare and Progressive Liver Disease This program highlights the broader potential of ACLY biology
Page 19
FY 2026 Operating Expense Guidance © 2025 Esperion Therapeutics, Inc. All rights reserved.19 1. Includes ~$15 million of non-cash stock-based compensation expense • Reflects continued investment in U.S. commercial execution • Supports advancement of pipeline programs, including ESP-2001 and triple combination program • Maintains focus on disciplined spend and return on investment FY 2026 R&D Guidance $40 – 50 M FY 2026 SG&A Guidance $170 – 195 M FY 2026 OpEx Guidance1 $210 – 245 M
Page 20
From Execution to Ambition © 2025 Esperion Therapeutics, Inc. All rights reserved.20 Achieve at least 5 marketed products by 2040 through a combination of BD and internal pipeline advancement Strengthen and Expand the Bempedoic Acid Franchise Build a Diversified, Multi-Product Portfolio Advance the Next- Generation ACLY Pipeline • Continue to unlock the multi billion-dollar potential of the NEXLETOL/NEXLIZET franchise • Leverage established U.S. commercial infrastructure to support product acquisitions, co-promotions, in-licensing, and revenue-share partnerships • Build a diversified portfolio of internally developed, wholly owned ACLY inhibitors globally targeting rare and orphan diseases
Page 21
© 2025 Esperion Therapeutics, Inc. All rights reserved.21 Experienced Leaders, Breakthrough Results PRESIDENT AND CHIEF EXECUTIVE OFFICER Sheldon Koenig CHIEF FINANCIAL OFFICER Ben Halladay CHIEF COMMERCIAL OFFICER John Harlow CHIEF BUSINESS OFFICER Betty Jean Swartz CHIEF TECHNICAL OPERATIONS OFFICER Glenn Brame GENERAL COUNSEL Ben Looker, Esq. VP, EARLY & PRE-CLINICAL DRUG DISCOVERY Stephen Pinkosky VP, CLINICAL DEVELOPMENT LeAnne Bloedon VP, HUMAN RESOURCES Heather Persh VP, GLOBAL REGULATORY AFFAIRS Satish Nachaegari
Page 22
Important Safety Information
Page 23
NEXLETOL® (bempedoic acid) Important Safety Information © 2025 Esperion Therapeutics, Inc. All rights reserved.23 • NEXLIZET is indicated: • The bempedoic acid component of NEXLIZET and NEXLETOL is indicated to reduce the risk of myocardial infarction and coronary revascularization in adults who are unable to take recommended statin therapy (including those not taking a statin) with: • established cardiovascular disease (CVD), or • at high risk for a CVD event but without established CVD. • As an adjunct to diet: • NEXLIZET, alone or in combination with other LDL-C lowering therapies, to reduce LDL-C in adults with primary hyperlipidemia, including HeFH. • NEXLETOL, in combination with other LDL-C lowering therapies, or alone when concomitant LDL-C lowering therapy is not possible, to reduce LDL-C in adults with primary hyperlipidemia, including HeFH. • NEXLETOL is contraindicated in patients with a prior serious hypersensitivity reaction to bempedoic acid or any of the excipients. Serious hypersensitivity reactions, such as angioedema, have occurred. • Hyperuricemia: NEXLETOL may increase blood uric acid levels, which may lead to gout. Hyperuricemia may occur early in treatment and persist throughout treatment, returning to baseline following discontinuation of treatment. Assess uric acid levels periodically as clinically indicated. Monitor for signs and symptoms of hyperuricemia, and initiate treatment with urate-lowering drugs as appropriate. • Tendon Rupture: NEXLETOL is associated with an increased risk of tendon rupture or injury. Tendon rupture may occur more frequently in patients over 60 years of age, in those taking corticosteroid or fluoroquinolone drugs, in patients with renal failure, and in patients with previous tendon disorders. Discontinue NEXLETOL at the first sign of tendon rupture. Consider alternative therapy in patients who have a history of tendon disorders or tendon rupture. • The most common adverse reactions in the primary hyperlipidemia trials of NEXLETOL in ≥2% of patients and greater than placebo were upper respiratory tract infection, muscle spasms, hyperuricemia, back pain, abdominal pain or discomfort, bronchitis, pain in extremity, anemia, and elevated liver enzymes. • The most common adverse reactions in the cardiovascular outcomes trial for NEXLETOL at an incidence of ≥2% and 0.5% greater than placebo were hyperuricemia, renal impairment, anemia, elevated liver enzymes, muscle spasms, gout, and cholelithiasis. • Discontinue NEXLETOL when pregnancy is recognized unless the benefits of therapy outweigh the potential risks to the fetus. Because of the potential for serious adverse reactions in a breast-fed infant, breastfeeding is not recommended during treatment with NEXLETOL. • Report pregnancies to Esperion Therapeutics, Inc. Adverse Event reporting line at 1-833-377-7633. See full prescribing information here.
Page 24
NEXLIZET® (bempedoic acid and ezetimibe) Important Safety Information © 2025 Esperion Therapeutics, Inc. All rights reserved.24 • NEXLIZET is indicated: • The bempedoic acid component of NEXLIZET and NEXLETOL is indicated to reduce the risk of myocardial infarction and coronary revascularization in adults who are unable to take recommended statin therapy (including those not taking a statin) with: • established cardiovascular disease (CVD), or • at high risk for a CVD event but without established CVD. • As an adjunct to diet: • NEXLIZET, alone or in combination with other LDL-C lowering therapies, to reduce LDL-C in adults with primary hyperlipidemia, including HeFH. • NEXLETOL, in combination with other LDL-C lowering therapies, or alone when concomitant LDL-C lowering therapy is not possible, to reduce LDL-C in adults with primary hyperlipidemia, including HeFH. • NEXLIZET is contraindicated in patients with a prior hypersensitivity to ezetimibe or bempedoic acid or any of the excipients. Serious hypersensitivity reactions, such as anaphylaxis, angioedema, rash, and urticaria have been reported with ezetimibe or bempedoic acid. • Hyperuricemia: Bempedoic acid, a component of NEXLIZET, may increase blood uric acid levels, which may lead to gout. Hyperuricemia may occur early in treatment and persist throughout treatment, returning to baseline following discontinuation of treatment. Assess uric acid levels periodically as clinically indicated. Monitor for signs and symptoms of hyperuricemia, and initiate treatment with urate-lowering drugs as appropriate. • Tendon Rupture: Bempedoic acid, a component of NEXLIZET, is associated with an increased risk of tendon rupture or injury. Tendon rupture may occur more frequently in patients over 60 years of age, in those taking corticosteroid or fluoroquinolone drugs, in patients with renal failure, and in patients with previous tendon disorders. Discontinue NEXLIZET at the first sign of tendon rupture. Consider alternative therapy in patients who have a history of tendon disorders or tendon rupture. • The most common adverse reactions in the primary hyperlipidemia trials of bempedoic acid (a component of NEXLIZET) in ≥2% of patients and greater than placebo were upper respiratory tract infection, muscle spasms, hyperuricemia, back pain, abdominal pain or discomfort, bronchitis, pain in extremity, anemia, and elevated liver enzymes. • Adverse reactions reported in ≥2% of patients treated with ezetimibe (a component of NEXLIZET) and at an incidence greater than placebo in clinical trials were upper respiratory tract infection, diarrhea, arthralgia, sinusitis, pain in extremity, fatigue, and influenza. • In the primary hyperlipidemia trials of NEXLIZET, the most commonly reported adverse reactions (incidence ≥3% and greater than placebo) observed with NEXLIZET, but not observed in clinical trials of bempedoic acid or ezetimibe, were urinary tract infection, nasopharyngitis, and constipation. • The most common adverse reactions in the cardiovascular outcomes trial of bempedoic acid (a component of NEXLIZET) at an incidence of ≥2% and 0.5% greater than placebo were hyperuricemia, renal impairment, anemia, elevated liver enzymes, muscle spasms, gout, and cholelithiasis. • Discontinue NEXLIZET when pregnancy is recognized unless the benefits of therapy outweigh the potential risks to the fetus. Because of the potential for serious adverse reactions in a breast- fed infant, breastfeeding is not recommended during treatment with NEXLIZET. • Report pregnancies to Esperion Therapeutics, Inc. Adverse Event reporting line at 1-833-377-7633. See full prescribing information here .